ST. LOUIS — Individuals are suing an international pharmaceutical company citing alleged breach of implied warranty.
James Bollingmo, Marvin Campbell, Lynwood Darby Sr., Noel Fitzgerald, Shirley Gainey, et. al. filed a complaint Sept. 13 in the St. Louis 22nd Judicial Circuit Court against Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GMBH, Boehringer Ingelheim Roxane Inc., Boehringer Ingelheim Pharma GMBH & Co., KG and Bidachem S.P.A., alleging they failed to warn physicians and consumers of the risks associated with the use of Pradaxa.
According to the complaint, the plaintiffs allege that in 2010, the Food and Drug Administration approved Pradaxa as an oral anticoagulant to reduce the risk of stroke and systematic embolism in adults with nonvalvular atrial fibrillation. The plaintiffs claim the product has harmful effects that were never disclosed to physicians and patients. As a result, the plaintiffs say they have suffered injuries that led to untimely death to some patients.
The plaintiffs hold the defendants responsible because they allegedly failed to provide appropriate warnings and instructions about the dangers posed by Pradaxa, failed to conduct adequate safety and efficacy studies before marketing the product and failed to design a product that was not capable of causing personal injuries and death.
The plaintiffs request a trial by jury and seek judgment for general, compensatory and punitive damages, costs of action and further relief the court deems just and appropriate. They are represented by John J. Driscoll of The Driscoll Firm PC in St. Louis.
St. Louis 22nd Judicial Circuit Court case number 1722-CC11322